Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 400 of 427 entries
View as:

A Non-interventional Study of REVLIMID® (Lenalidomide) Treatment of IPSS Low- or Intermediate-1-risk Myelodysplastic Syndromes Associated With a Deletion 5q or Refractory/Relapsed Mantle Cell Lymphoma in Korea

Phase: N/A Priority: Normal
NCT ID: NCT04036448 Org: User:
Start: 11/28/19 End: 08/15/23 Due: 08/15/24

Connect® Myeloid Disease Registry

Phase: N/A Priority: Normal
NCT ID: NCT01688011 Org: User:
Start: 12/12/13 End: 03/31/31 Due: 03/31/32

Pharmacokinetic and Safety Study of Nab®-Paclitaxel (ABI-007) Plus Gemcitabine in Subjects With Advanced Pancreatic Cancer Who Have Cholestatic Hyperbilirubinemia

Phase: N/A Priority: Normal
NCT ID: NCT02267707 Org: User:
Start: 05/27/15 End: 02/10/16 Due: 02/10/17

A Safety and Efficacy Study of CC-90011 in Combination With Nivolumab in Subjects With Advanced Cancers

Phase: N/A Priority: Normal
NCT ID: NCT04350463 Org: User:
Start: 07/14/20 End: 12/19/23 Due: 12/19/24

Connect® MM- The Multiple Myeloma Disease Registry

Phase: N/A Priority: Normal
NCT ID: NCT01081028 Org: User:
Start: 09/01/09 End: 08/15/31 Due: 08/15/32

Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

Phase: N/A Priority: Normal
NCT ID: NCT02112175 Org: User:
Start: 04/30/14 End: 10/12/20 Due: 10/12/21

Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01497093 Org: User:
Start: 02/15/12 End: 07/23/19 Due: 07/23/20

Japanese Phase 1 Study to Evaluate Tolerated Dose, Safety, and Efficacy of Pomalidomide in Patients With Refractory or Relapsed and Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01568294 Org: User:
Start: 04/01/12 End: 07/08/15 Due: 07/08/16

A Study to Assess Safety, Tolerability, and Pharmacokinetics of CC-92480 Formulations in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT04839809 Org: User:
Start: 01/19/21 End: 10/08/21 Due: 10/08/22

Relative Bioavailability Study of CC-292

Phase: N/A Priority: Normal
NCT ID: NCT02433457 Org: User:
Start: 05/26/14 End: 09/26/14 Due: 09/26/15

Study of Ozanimod (RPC1063) in Relapsing Multiple Sclerosis (MS)

Phase: N/A Priority: Normal
NCT ID: NCT02294058 Org: User:
Start: 12/03/14 End: 12/22/16 Due: 12/22/17

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT00394251 Org: User:
Start: 08/01/06 End: 02/01/08 Due: 02/01/09

A Study to Evaluate the Drug Levels, Metabolism and Excretion, and Absolute Bioavailability of BMS-986365 in Healthy Male Participants

Phase: N/A Priority: Normal
NCT ID: NCT06433505 Org: User:
Start: 05/30/24 End: 02/28/25 Due: 02/28/26

Study to Determine the Safety and Tolerability of Sotatercept (ACE-011) in Adults With Beta( β)- Thalassemia.

Phase: N/A Priority: Normal
NCT ID: NCT01571635 Org: User:
Start: 10/10/12 End: 05/24/22 Due: 05/24/23

Study to Evaluate Pharmacokinetics, Food Effect, Safety and Efficacy of Oral Azacitidine

Phase: N/A Priority: Normal
NCT ID: NCT01519011 Org: User:
Start: 02/07/12 End: 05/12/15 Due: 05/12/16

A Study to Compare the Efficacy and Safety of JCAR017 to Standard of Care in Adult Subjects With High-risk, Transplant-eligible Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphomas

Phase: N/A Priority: Normal
NCT ID: NCT03575351 Org: User:
Start: 10/23/18 End: 10/23/23 Due: 10/23/24

Abraxane in Treatment of Metastatic Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02555696 Org: User:
Start: 05/31/12 End: 12/31/16 Due: 12/31/17

A Study to Evaluate the Relationship of Lenalidomide With Tumor Flare Reaction and High Tumor Burden in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Phase: N/A Priority: Normal
NCT ID: NCT03647124 Org: User:
Start: 03/13/19 End: 01/10/24 Due: 01/10/25

An Extension Study of Oral Ozanimod for Moderately to Severely Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT03467958 Org: User:
Start: 08/24/18 End: 10/31/24 Due: 10/31/25

Pharmacokinetic Study of Thalidomide in Subjects With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01937442 Org: User:
Start: 11/07/13 End: 09/23/15 Due: 09/23/16

A Safety Study of ABI-007 for In-Stent Restenosis

Phase: N/A Priority: Normal
NCT ID: NCT00093223 Org: User:
Start: 09/01/01 End: 12/01/07 Due: 12/01/08

Trial of Romidepsin and Bortezomib for Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT00765102 Org: User:
Start: 09/01/08 End: 03/01/10 Due: 03/01/11

Post-authorisation Study of Biological Relapse in Patients With Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT02394210 Org: User:
Start: 05/14/13 End: 05/18/21 Due: 05/18/22

A Study of Efficacy and Safety of Mongersen (GED-0301) for the Treatment of Adult and Adolescent Subjects With Active Crohn's Disease

Phase: N/A Priority: Normal
NCT ID: NCT02974322 Org: User:
Start: 12/01/17 End: 12/24/18 Due: 12/24/19

Study of Lenalidomide and Low-Dose Dexamethasone in Chinese Subjects With Relapsed/Refractory Multiple Myeloma

Phase: N/A Priority: Normal
NCT ID: NCT01593410 Org: User:
Start: 08/01/10 End: 01/03/13 Due: 01/03/14